Neutrophil hyperchemotaxis in Behçet's disease: a possible role for monocytes orchestrating bacterial-induced innate immune responses.
Increased neutrophil chemotaxis and hyperresponsiveness to streptococci have been considered to play a role in Behçet's disease (BD) pathogenesis. Our aim was to correlate TLR2 expression and chemotactic responses stimulated by bacterial lipoteichoic acid (LTA) in BD neutrophils. Thus, we assessed expressions of TLR2 and the correlate receptors CD14, CD114 (G-CSF receptor), CD116 (GM-CSF receptor) and also TLR4 on circulating neutrophils and monocytes of patients with active BD. Serum concentration of soluble CD14 (sCD14) was also measured. Neutrophil chemotactic responses from BD patients and healthy controls under LTA stimulation were assessed. Disease activity was evaluated by Behçet's Disease Current Activity Form (BDCAF). Receptor expressions were measured by flow cytometry, neutrophil chemotaxis was assessed in a Boyden chamber and sCD14 was measured by enzyme-linked immunosorbent assay. TLR2 expression was higher only on BD monocytes compared with healthy controls (39.9 +/- 13.1 vs. 33.6 +/- 5.3, p = 0.019). Expressions of all other receptors were similar in BD and control group. Of particular interest, TLR2 expression on neutrophils was similar in both groups and, when stimulated with LTA, BD neutrophils showed chemotactic responses similar to the controls. Neutrophils exhibited increased chemotaxis only when incubated with BD plasma. Serum sCD14 concentration was higher in BD patients than in controls (1,920.8 +/- 563.6 vs. 1,623.2 +/- 391.3 ng/ml, p = 0.008), and it was positively correlated with both CD14 expression on circulating monocytes membrane (p = 0.035) and BDCAF scores (p = 0.025). In conclusion, isolated BD neutrophils do not overexpress TLR2 neither overreact to LTA. However, because TLR2 expression was higher on BD monocytes, sCD14 from monocyte origin correlated with disease activity and neutrophil hyperchemotaxis occurred on strict dependence of plasmatic soluble factors, we suggest a possible role for bacterial stimulation of monocytes via TLR2 producing neutrophil-stimulating pro-inflammatory factors in BD.
Neves
Fabricio Souza
FS
Rheumatology Division, Faculdade de Medicina, University of São Paulo (USP), São Paulo, Brazil. nevesfab@bol.com.br
Carrasco
Solange
S
Goldenstein-Schainberg
Cláudia
C
Gonçalves
Célio Roberto
CR
de Mello
Suzana Beatriz Veríssimo
SB
D000293:Adolescent; D000328:Adult; D015703:Antigens, CD / Q000097:blood; D001528:Behcet Syndrome / Q000097:blood / Q000276:immunology* / Q000503:physiopathology; D015415:Biomarkers / Q000097:blood; D002478:Cells, Cultured; D002630:Chemotactic Factors / Q000494:pharmacology; D002634:Chemotaxis, Leukocyte / Q000187:drug effects / Q000276:immunology*; D005260:Female; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology*; D008070:Lipopolysaccharides / Q000494:pharmacology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects / Q000276:immunology*; D018375:Neutrophil Activation; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*; D012720:Severity of Illness Index; D013682:Teichoic Acids / Q000494:pharmacology; D051193:Toll-Like Receptors / Q000097:blood; D055815:Young Adult
D015703:Antigens, CD; D015415:Biomarkers; D002630:Chemotactic Factors; D008070:Lipopolysaccharides; D013682:Teichoic Acids; D051193:Toll-Like Receptors; C009900:lipoteichoic acid
J Rheumatol. 2000 Mar;27(3):708-13
10743813
J Immunol. 2003 May 15;170(10):5268-75
12734376
Rheumatology (Oxford). 2008 Jun;47(6):840-8
18411217
J Immunol. 2000 Mar 1;164(5):2674-83
10679108
Science. 1991 May 31;252(5010):1321-2
1718034
J Immunol. 2004 Apr 1;172(7):4470-9
15034063
Rheumatol Int. 2008 Mar;28(5):401-6
17934735
J Rheumatol. 2002 Nov;29(11):2393-6
12415598
J Rheumatol. 1993 Sep;20(9):1544-9
8164212
J Clin Pathol. 1977 Mar;30(3):250-3
845272
Arthritis Rheum. 2008 Feb;58(2):338-48
18240239
Clin Rheumatol. 2007 Aug;26(8):1263-7
17180637
Ann Rheum Dis. 2001 Nov;60(11):1074-6
11602484
Blood. 2002 Sep 1;100(5):1860-8
12176910
Clin Exp Immunol. 2008 May;152(2):245-51
18336589
Clin Exp Rheumatol. 2005 Jul-Aug;23(4 Suppl 38):S27-34
16273761
J Rheumatol. 1997 Jul;24(7):1332-6
9228133
Ann Med Interne (Paris). 1999 Oct;150(6):483-7
10615534
Lancet. 1975 Oct 25;2(7939):813
78172
Rheumatology (Oxford). 2006 Dec;45(12):1461-5
16998234
Arthritis Rheum. 1996 Dec;39(12):2062-5
8961912
J Biol Chem. 2003 May 2;278(18):15587-94
12594207
Curr Opin Rheumatol. 2004 Jan;16(1):38-42
14673387
J Leukoc Biol. 2004 Mar;75(3):467-77
14673018
Ann Rheum Dis. 1999 Oct;58(10):658
10577375
Immunology. 2008 Feb;123(2):171-80
17662043
J Rheumatol. 1989 Apr;16(4):506-11
2664172
J Leukoc Biol. 1997 Feb;61(2):173-8
9021923
Clin Exp Immunol. 1990 Mar;79(3):353-60
2180598
Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2744-8
7681988
J Pharmacobiodyn. 1984 Oct;7(10):747-54
6520696
Nature. 1997 Jul 24;388(6640):394-7
9237759
Br J Rheumatol. 1996 May;35(5):424-9
8646431
Lancet. 1990 May 5;335(8697):1078-80
1970380
Rheumatology (Oxford). 1999 Aug;38(8):728-33
10501420
Arthritis Res Ther. 2008;10(1):R16
18234118
Clin Exp Rheumatol. 2007 Jul-Aug;25(4 Suppl 45):S27-33
17949548
Immunology. 2005 May;115(1):90-8
15819701